Table II.

Randomized controlled trials

First author, year	Country	Control group	Sample size	Infections		Sample size	Sample size	Infections
				n	%			n	%
Morales, 2000	Spain	Placebo	287	6	2.09	Cefazolin 2 g. i.v.	237	4	1.7
Yerdel, 2001	Turkey	Placebo	133	12	9.0	Ampicillin + sulbactam 1.5 g. i.v.	136	1	0.7
Aufenacker, 2004	Netherlands	Placebo	505	9	1.8	Cefazolin 1 g. i.v.	503	8	1.6
Celdran, 2004	Spain	Placebo	49	4	8	Cefazolin 1 g. i.v..	50	0	0
Oteiza, 2004	Spain	No treatment	123	0	0	Amoxicillin + clavulanic acid 2 g i.v.	124	1
Perez, 2005	Philippines	Placebo	180	7	3.9	Cefazolin 1 g. i.v.	180	4	2.2
Tzoravas, 2007	Greece	Placebo	193	9	4.6	Amoxicillin + clavulanic acid 1.2 g. i.v.	193	5	2.6
Jain, 2008	India	Placebo	60	1	1.7	Amoxicillin + clavulanic acid 1.2 g. i.v.	60	1	1.7
Shankar, 2010	India	Placebo	162	17	10.5	Cefazolin 1 g .i.v.	172	12	7
Ergul, 2011	Turkey	Placebo	100	7	7	Cefazolin 1 g .i.v.	100	5	5
Othman, 2011	Egypt	Placebo	48	6	2.88	Amoxicillin + clavulanic acid 1.2 g. i.v.	50	4	2
Mazaki, 2013	Japan	Placebo	100	13	13	Cefazolin 1 g. i.v.	100	2	2
			1940	91	4.7		1905	47	2.5